Fulcrum Therapeutics, Inc. (FULC)
3.76
-0.03
(-0.79%)
USD |
NASDAQ |
Sep 15, 11:07
Fulcrum Therapeutics Enterprise Value : -24.44M for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | -24.44M |
| September 11, 2026 | -23.68M |
| September 10, 2026 | -23.68M |
| September 09, 2026 | -20.63M |
| September 08, 2026 | -22.15M |
| September 04, 2026 | -19.86M |
| September 03, 2026 | -20.63M |
| September 02, 2026 | -19.86M |
| September 01, 2026 | -18.34M |
| August 31, 2026 | -16.81M |
| August 28, 2026 | -19.86M |
| August 27, 2026 | -19.86M |
| August 26, 2026 | -19.10M |
| August 25, 2026 | -19.10M |
| August 24, 2026 | -20.63M |
| August 21, 2026 | -21.39M |
| August 20, 2026 | -19.86M |
| August 19, 2026 | -15.29M |
| August 18, 2026 | -18.34M |
| August 17, 2026 | -20.63M |
| August 14, 2026 | -28.26M |
| August 13, 2026 | -30.54M |
| August 12, 2026 | -29.78M |
| August 11, 2026 | -32.07M |
| August 10, 2026 | -27.49M |
| Date | Value |
|---|---|
| August 07, 2026 | -16.81M |
| August 06, 2026 | -25.97M |
| August 05, 2026 | -25.97M |
| August 04, 2026 | -23.68M |
| August 03, 2026 | -30.54M |
| July 31, 2026 | -40.46M |
| July 30, 2026 | -29.78M |
| July 29, 2026 | -37.41M |
| July 28, 2026 | -29.78M |
| July 27, 2026 | -29.02M |
| July 24, 2026 | -29.78M |
| July 23, 2026 | -26.73M |
| July 22, 2026 | -31.31M |
| July 21, 2026 | -32.83M |
| July 20, 2026 | -37.41M |
| July 17, 2026 | -35.12M |
| July 16, 2026 | -46.56M |
| July 15, 2026 | -41.99M |
| July 14, 2026 | -39.70M |
| July 13, 2026 | -43.51M |
| July 10, 2026 | -46.56M |
| July 09, 2026 | -39.70M |
| July 08, 2026 | -29.02M |
| July 07, 2026 | -25.97M |
| July 06, 2026 | -29.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.23M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -11.18M |
| Definium Therapeutics, Inc. | 4.361B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.18M |
| Total Expenses (Quarterly) | 26.18M |
| EPS Diluted (Quarterly) | -0.3433 |
| Earnings Yield | -32.27% |
| Normalized Earnings Yield | -29.97 |